Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 192

1.

The serum levels of connective tissue growth factor in patients with systemic lupus erythematosus and lupus nephritis.

Wang FM, Yu F, Tan Y, Liu G, Zhao MH.

Lupus. 2014 Jun;23(7):655-64. doi: 10.1177/0961203314524291. Epub 2014 Feb 17.

PMID:
24536044
2.

Elevated serum level of growth arrest-specific protein 6 (Gas6) in systemic lupus erythematosus patients is associated with nephritis and cutaneous vasculitis.

Wu CS, Hu CY, Tsai HF, Chyuan IT, Chan CJ, Chang SK, Hsu PN.

Rheumatol Int. 2014 May;34(5):625-9. doi: 10.1007/s00296-013-2882-1. Epub 2013 Nov 1.

PMID:
24178067
3.

Pentraxin 3 Is Closely Associated With Tubulointerstitial Injury in Lupus Nephritis: A Large Multicenter Cross-Sectional Study.

Pang Y, Tan Y, Li Y, Zhang J, Guo Y, Guo Z, Zhang C, Yu F, Zhao MH.

Medicine (Baltimore). 2016 Jan;95(3):e2520. doi: 10.1097/MD.0000000000002520.

4.

Up regulation of serum tumor necrosis factor-related apoptosis inducing ligand in juvenile-onset systemic lupus erythematosus: relations with disease activity, antibodies to double -stranded DNA, nephritis and neutropenia.

Ezzat MH, El-Gammasy TM, Shaheen KY, El-Mezdawi RA, Youssef MS.

Int J Rheum Dis. 2013 Jun;16(3):310-8. doi: 10.1111/1756-185X.12061. Epub 2013 Apr 27.

PMID:
23981753
5.

Autoantigen microarrays reveal autoantibodies associated with proliferative nephritis and active disease in pediatric systemic lupus erythematosus.

Haddon DJ, Diep VK, Price JV, Limb C, Utz PJ, Balboni I.

Arthritis Res Ther. 2015 Jun 17;17:162. doi: 10.1186/s13075-015-0682-6.

6.

Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis.

Sjöwall C, Zickert A, Skogh T, Wetterö J, Gunnarsson I.

Arthritis Res Ther. 2009;11(6):R188. doi: 10.1186/ar2880. Epub 2009 Dec 11.

7.

Elevated serum levels of syndecan-1 are associated with renal involvement in patients with systemic lupus erythematosus.

Kim KJ, Kim JY, Baek IW, Kim WU, Cho CS.

J Rheumatol. 2015 Feb;42(2):202-9. doi: 10.3899/jrheum.140568. Epub 2014 Dec 15.

PMID:
25512478
8.
9.

Insulin-like growth factor binding protein-2 as a novel biomarker for disease activity and renal pathology changes in lupus nephritis.

Ding H, Kharboutli M, Saxena R, Wu T.

Clin Exp Immunol. 2016 Apr;184(1):11-8. doi: 10.1111/cei.12743. Epub 2016 Jan 11.

PMID:
26616478
10.

Antiphospholipid syndrome nephropathy (APSN) in patients with lupus nephritis: a retrospective clinical and renal pathology study.

Erre GL, Bosincu L, Faedda R, Fenu P, Masala A, Sanna M, Taras L, Longu MG, Piras M, Soro G, Satta AE, Passiu G.

Rheumatol Int. 2014 Apr;34(4):535-41.

PMID:
24232504
11.

Plasma-soluble urokinase-type plasminogen activator receptor levels are associated with clinical and pathological activities in lupus nephritis: a large cohort study from China.

Qin DD, Song D, Huang J, Yu F, Zhao MH.

Lupus. 2015 May;24(6):546-57. doi: 10.1177/0961203314558857. Epub 2014 Nov 18.

PMID:
25411257
12.

Urinary MCP-1 as diagnostic and prognostic marker in patients with lupus nephritis flare.

Singh RG, Usha, Rathore SS, Behura SK, Singh NK.

Lupus. 2012 Oct;21(11):1214-8. doi: 10.1177/0961203312452622. Epub 2012 Jun 27.

PMID:
22759858
13.

Frequency of class III and IV nephritis in systemic lupus erythematosus without clinical renal involvement: an analysis of predictive measures.

Wakasugi D, Gono T, Kawaguchi Y, Hara M, Koseki Y, Katsumata Y, Hanaoka M, Yamanaka H.

J Rheumatol. 2012 Jan;39(1):79-85. doi: 10.3899/jrheum.110532. Epub 2011 Nov 15.

PMID:
22089455
14.

Angiopoietin-2, endothelial dysfunction and renal involvement in patients with systemic lupus erythematosus.

El-Banawy HS, Gaber EW, Maharem DA, Matrawy KA.

J Nephrol. 2012 Jul-Aug;25(4):541-50. doi: 10.5301/jn.5000030.

PMID:
21956768
15.

Relationship between lupus nephritis activity and the serum level of soluble VCAM-1.

Ikeda Y, Fujimoto T, Ameno M, Shiiki H, Dohi K.

Lupus. 1998;7(5):347-54.

PMID:
9696139
16.

Serum cystatin C is independently associated with renal impairment and high sensitivity C-reactive protein in systemic lupus erythematosus.

Chew C, Pemberton PW, Husain AA, Haque S, Bruce IN.

Clin Exp Rheumatol. 2013 Mar-Apr;31(2):251-5. Epub 2012 Dec 17.

PMID:
23306163
17.

Elevated serum anti-endothelial cell autoantibodies titer is associated with lupus nephritis in patients with systemic lupus erythematosus.

Tseng JC, Lu LY, Hu RJ, Kau CK, Cheng HH, Lin PR, Sun CW, Liang HT, Lam HC, Tai MH.

J Microbiol Immunol Infect. 2007 Feb;40(1):50-5.

PMID:
17332907
18.

Urinary prostaglandin D synthase as biomarker in lupus nephritis: a longitudinal study.

Gupta R, Yadav A, Misra R, Aggarwal A.

Clin Exp Rheumatol. 2015 Sep-Oct;33(5):694-8. Epub 2015 Jul 23.

PMID:
26211517
19.

Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4.

Julkunen H, Ekblom-Kullberg S, Miettinen A.

Rheumatol Int. 2012 Aug;32(8):2445-51. doi: 10.1007/s00296-011-1962-3. Epub 2011 Jun 26.

PMID:
21706294
20.

The levels of sCD30 and of sCD40L in a group of patients with systemic lupus erythematodes and their diagnostic value.

Ciferská H, Horák P, Hermanová Z, Ordeltová M, Zadrazil J, Tichý T, Scudla V.

Clin Rheumatol. 2007 May;26(5):723-8. Epub 2006 Nov 14. Erratum in: Clin Rheumatol. 2007 May;26(5):852.

PMID:
17103120
Items per page

Supplemental Content

Write to the Help Desk